# BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

> **NCT06745687** · NA · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- High Risk Smoldering Multiple Myeloma

## Interventions

- **DRUG:** CM336

## Key facts

- **NCT ID:** NCT06745687
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2026-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06745687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06745687, "BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06745687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*